X

Trial Profile

A Dose-Escalation Study of R1507 [RO4858696] in Patients With Advanced Solid Tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teprotumumab (Primary)
Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

26 Mar 2021 Results of a population PK analysis using data from three clinical studies: NCT00400361, NCT01868997 and NCT03461211 published in the Clinical Pharmacokinetics
23 Sep 2020 Results assessing pharmacokinetics and exposure-response relationship of Teprotumumab in this and Phase 2 and 3 studies presented at the 2020 American College of Clinical Pharmacology Annual Meeting
14 May 2020 Results published in the Horizon Therapeutics plc Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com